Skip to main content

Table 4 mem-PankoMabGEX staining is an independent prognosticator for advanced 10-year and overall survival

From: Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients

 

10-year survival

Overall survival

  

95% CI

  

95% CI

 

Covariate

Coefficient (b i )

[HR Exp (b i )]

Lower

Upper

P-value

Coefficient (b i )

[HR Exp (b i )]

Lower

Upper

P-value

Histology (NST vs. other)

−0.49

0.61

0.16

2.38

ns

−0.31

0.73

0.23

2.34

ns

Grading (G1. G2 vs. G3)

−0.51

0.60

0.18

1.97

ns

−0.59

0.55

0.19

1.63

ns

pT (pT1 vs. pT2-pT4)

−0.17

0.84

0.30

2.36

ns

−0.06

0.94

0.39

2.26

ns

pN (pN0 vs. pN1-pN3)

0.61

1.84

0.63

5.40

ns

1.06

2.89

1.11

7.53

.030

CIS (fraction within the invasive carcinoma) (no vs. yes)

0.08

1.08

0.40

2.97

ns

0.28

1.32

0.57

3.06

ns

ER (neg. vs. pos.)

−1.53

0.22

0.05

0.94

.041

−1.66

0.19

0.05

0.80

.023

PR (neg. vs. pos.)

0.10

1.10

0.28

4.28

ns

0.37

1.45

0.43

4.91

ns

Her2 (neg. vs. pos.)

0.92

2.52

0.56

11.35

ns

0.67

1.95

0.46

8.20

ns

age (≤55y vs. > 55 y.)

0.75

2.11

0.71

6.30

ns

0.28

1.32

0.55

3.18

ns

mem-PankoMabGEX™ (neg. vs. pos.)

−2.42

0.09

0.01

0.70

.022

−1.21

0.30

0.09

0.96

.042